India
1.1
hi-tec city, hyderabad
Add Favorite
Report Supplier
Business Description
We are gene 21 diagnostics pvt ltd based in hyderabad, India. We are member of companiess.com since December, 2007. Our business is related to Beauty & Personal Care industry and we specifically deal in diagnostic kits. Please find our product details below:elisa and chemiuluminescence immune kitsGene21 Diagnostics Pvt Ltd is a pio-neer biotechnology company withoperations in India and USA focusedin the manufacturing and commer-cialization of Immunological andMolecular Diagnostic products.Our Mission Statement:To make the best quality tests, sellat fair and competitive pricesworldwide, ship fast, share ourproducts and profitability withother partnered manufacturers anddistributorselisa and chemiuluminescence immune kitsGene21 Diagnostics Pvt Ltd is a pio-neer biotechnology company withoperations in India and USA focusedin the manufacturing and commer-cialization of Immunological andMolecular Diagnostic products.Our Mission Statement:To make the best quality tests, sellat fair and competitive pricesworldwide, ship fast, share ourproducts and profitability withother partnered manufacturers anddistributorsThank you for taking the time to go through our business profile. If there are any question, inquiry or comments, please feel free to contact us.
Business Overview
Avg Response Time
≤ 1h
Export Capabilities
Declared by supplierGene 21 Diagnostics Pvt Ltd has been exporting since 2007.
Export start year
2007
Trade Capabilities
Business Terms
Trade Ability
Diagnostic Kits market insight
As of 14 November 2026, 9 suppliers in 6 countries offer 9 active supply listings on Freshdi across Medical & HealthCare, the group Diagnostic Kits belongs to. Suppliers across Medical & HealthCare, the wider group Diagnostic Kits belongs to, come from 6 countries, led by India at 22.2%, on Freshdi as of 14 November 2026. Buyer inquiry volume across Medical & HealthCare, the wider group Diagnostic Kits belongs to, rose 100% on Freshdi in the 30 days to 14 November 2026 against the 30 days before, with 103.41% volatility in monthly inquiry and quotation activity over 338 days.
